# De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
20/02/2012		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/02/2012	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
29/10/2021	Cancer			

### Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-side-effects-treatment-throat-cancer-de-escalate-hpv

### Study website

http://www.warwick.ac.uk/go/deescalate

### Contact information

### Type(s)

Scientific

#### Contact name

Mrs Tessa Fulton-Lieuw

#### Contact details

Warwick Clinical Trials Unit Division of Health Sciences Warwick Medical School The University of Warwick Coventry United Kingdom CV4 7AL +44 2476 574 880 M.T.Fulton-Lieuw@warwick.ac.uk

### Additional identifiers

EudraCT/CTIS number 2011-005165-21

**IRAS** number

ClinicalTrials.gov number NCT01874171

Secondary identifying numbers 11723

# Study information

#### Scientific Title

De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma: a randomised controlled trial

### **Acronym**

De-ESCALaTE HPV

### Study objectives

Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection. HPV+ OPSCC is considered a distinct disease entity, affecting younger patients and has a good prognosis following treatment. Subsequently, patients can live with the considerable side effects for several decades.

Radiotherapy and cetuximab have demonstrated similar efficacy to platin chemoradiotherapy in head and neck cancer, but is potentially less toxic.

Results of this trial will be used to determine the optimum treatment of this debilitating cancer, with the primary aim of decreasing toxicity and improving quality of life for HPV+OPSCC patients.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

NRES Committee West Midlands Coventry & Warwickshire, 29/11/2011, ref: 11/WM/0381

### Study design

Both; Interventional; Design type: Treatment

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Head and Neck Cancer; Disease: Head and Neck

### **Interventions**

HPV positive patients will be randomised to receive either cisplatin + radiotherapy (Arm A) or cetuximab + radiotherapy (Arm B) and will be followed up for two years. Patients that are HPV negative will enter into the Registration Cohort Study.

Cetuximab, Initial dose of 400mg/m2, administered intravenously, 1 week before start of radiotherapy followed by 7 weekly doses of 250mg/m2, administered intravenously. during radiotherapy.

Cisplatin, Three doses of cisplatin 100mg/m2, administered intravenously, on days 1, 22 and 43 of radiotherapy.

### Intervention Type

Drug

### Phase

Phase III

### Drug/device/biological/vaccine name(s)

Cetuximab, cisplatin

### Primary outcome measure

Current primary outcome as of 13/03/2012:

Severe toxicity (acute and late) (Grade 3-5); Timepoint(s): Two years from end of treatment

Previous primary outcome:

Severe toxicity (Grade 3-5); Timepoint(s): Two years from end of treatment

### Secondary outcome measures

- 1. Acute severe toxicity; Timepoint(s): 3 months from end of treatment
- 2. Late severe toxicity; Timepoint(s): Two years from end of treatment

- 3. Quality of Life; Timepoint(s): Two years from end of treatment
- 4. Dysphagia; Timepoint(s): Two years from end of treatment
- 5. Cost effectiveness; Timepoint(s): Two years from end of treatment
- 6. Overall survival, recurrence and metastasis; Timepoint(s): Two years from end of treatment

### Overall study start date

01/09/2011

### Completion date

31/07/2019

# **Eligibility**

### Key inclusion criteria

Current inclusion criteria as of 13/03/2012:

- 1. Stage III-IVa oropharyngeal squamous cell tumours
- 2. Clinical multidisciplinary team decision to treat with primary curative chemoradiotherapy
- 3. No previous treatment for the primary tumour, including surgery, neck dissection or tracheostomy [except node biopsies or diagnostic tonsillectomy]
- 4. Medically fit Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2
- 5. Adequate cardiovascular, haematological, renal and hepatic function
- 6. Age 18 years or over
- 7. Written informed consent given
- 8. Using adequate contraception [male and female participants]. Must take contraceptive measures during, and for at least three months after treatment.

### Previous inclusion criteria:

- 1. Stage III-IVa oropharyngeal squamous cell tumours
- 2. Clinical multidisciplinary team decision to treat with primary curative chemoradiotherapy
- 3. No previous treatment for the primary tumour, including surgery, neck dissection or tracheostomy [except node biopsies or diagnostic tonsillectomy]
- 4. Medically fit Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2
- 5. Adequate cardiovascular, haematological, renal and hepatic function
- 6. Age 18 years or over
- 7. Written informed consent given
- 8. Using adequate contraception [male and female participants]

### Participant type(s)

Patient

### Age group

Adult

### Lower age limit

18 Years

### Sex

Both

### Target number of participants

Planned Sample Size: 304; UK Sample Size: 304; Description: Depending on the number of participants recruited by international sites, the UK sample size may be smaller.

### Total final enrolment

334

### Key exclusion criteria

Current exclusion criteria as of 13/03/2012:

- 1. Distant metastasis (i.e. stage IVc disease)
- 2. Tumor, Node, Metastasis (TNM) Stage T1-2N0 disease
- 3. Treated with primary radical surgery to the primary site e.g. resection
- 4. Concurrent use of CYP3A4 inducers or inhibitors
- 5. Serious cardiac illness or other medical conditions precluding the use of cisplatin or cetuximab
- 6. HPV+ patients who have p16+ tumours who also have N2b, N2c or N3 nodal disease and who also smoke more than 10 pack years (i.e. have both risk factors)
- 7. Pregnant or lactating
- 8. Previous treatment for any other cancer with cytotoxics, radiotherapy or antiEGFR therapies
- 9. Inadequate renal, haematological or liver functions
- 10. Patients with clinically significant hearing impairment.
- 11. Life expectancy less than three months
- 12. Other malignancy within the past three years except basal cell skin cancer or preinvasive carcinoma of the cervix

#### Previous exclusion criteria:

- 1. Distant metastasis (i.e. stage IVc disease)
- 2. Tumor, Node, Metastasis (TNM) Stage T1-2N0 disease
- 3. Treated with primary radical surgery to the primary site e.g. resection
- 4. Concurrent use of CYP3A4 inducers or inhibitors
- 5. Serious cardiac illness or other medical conditions precluding the use of cisplatin or cetuximab
- 6. HPV+ patients who have p16+ tumours who also have N2b, N2c or N3 nodal disease and who also smoke more than 10 pack years (i.e. have both risk factors)
- 7. Pregnant or lactating
- 8. Previous treatment for any other cancer with cytotoxics, radiotherapy or antiEGFR therapies
- 9. Inadequate renal, haematological or liver functions
- 10. Life expectancy less than three months
- 11. Other malignancy within the past three years except basal cell skin cancer or preinvasive carcinoma of the cervix

### Date of first enrolment

09/10/2012

#### Date of final enrolment

28/10/2016

### Locations

### Countries of recruitment

Belaium

England

Italy
Netherlands
Scotland

**United Kingdom** 

Wales

Ireland

Study participating centre Warwick Clinical Trials Unit University of Warwick Coventry United Kingdom CV4 7AL

### Study participating centre Aberdeen Royal Infirmary

Foresterhill Road Aberdeen United Kingdom AB25 2ZN

Study participating centre
St Luke's Centre for Radiation at Beaumont Hospital
Beaumont Road
Dublin
Ireland

\_

## Study participating centre Bradford Royal Infirmary

BIHR – Temple Bank House Bradford Royal Infirmary Bradford United Kingdom BD9 6RJ

### **Bristol Haematology & Oncology Centre**

Horfield Road Bristol United Kingdom BS2 8ED

# Study participating centre Castle Hill Hospital

Castle Road Cottingham United Kingdom HU16 5JQ

### Study participating centre Cheltenham General Hospital

Sandford Road Cheltenham United Kingdom GL53 7AN

### Study participating centre Clatterbridge Cancer Centre

Clatterbridge Road Bebington, Wirral United Kingdom CH63 4JY

### Study participating centre Colchester General Hospital

Turner Road Colchester Essex CO4 5JL Colchester United Kingdom CO4 5JL

# Study participating centre Glan Clwyd Hospital

North Wales Cancer Treatment Centre

Glan Clwyd Hospital Bodelwyddan Denbighshire Bodelwyddan United Kingdom LL18 5UJ

### Study participating centre James Cook University Hospital

Marton Road Middlesbrough United Kingdom TS4 3BW

### Study participating centre Leicester Royal Infirmary

Infirmary Square Leicester United Kingdom LE1 5WW

### Study participating centre Musgrove Park Hospital

The Beacon Centre Taunton United Kingdom TA1 5DA

### Study participating centre New Cross Hospital

Deansley Centre United Kingdom WV10 9PQ

### Study participating centre Nottingham City Hospital

Hucknall Road Nottingham United Kingdom NG5 1PB

### Study participating centre Queen Elizabeth Hospital Birmingham

Cancer Centre, Edgbaston Birmingham United Kingdom B15 2TH

# Study participating centre Royal Derby Hospital

Uttoxeter Road Derby United Kingdom DE22 3NE

### Study participating centre Royal Marsden Hospital (London)

Fulham Road London United Kingdom SW3 6JJ

### Study participating centre Royal Marsden Hospital (Sutton)

Downs Road Sutton Surrey Sutton, United Kingdom SM2 5PT

### Study participating centre Royal Surrey County Hospital

Egerton Road Guildford United Kingdom GU2 7XX

### Study participating centre

### **Royal United Hospital**

Combe Park Bath United Kingdom BA1 3NG

# Study participating centre Singleton Hospital

Sketty Lane Swansea United Kingdom SA2 8QA

### Study participating centre St James's Institute of Oncology

Beckett Street Leeds United Kingdom LS9 7TF

# Study participating centre St Luke's Hospital

Highfield Road Rathgar Dublin 6, Dublin Ireland

...

### Study participating centre University Hospitals Coventry & Warwickshire

Clifford Bridge Road Coventry United Kingdom CV2 2DX

Study participating centre Velindre Hospital Whitchurch Cardiff United Kingdom CF14 2TL

# Study participating centre VU University Medical Center

De Boelelaan 1117 Netherlands 1081 HV

### Study participating centre Manor Hospital

Moat Road Walsall United Kingdom WS2 9PS

### Study participating centre Western General Hospital

Crewe Road Edinburgh United Kingdom EH4 2XU

# Study participating centre Weston Park Hospital

Whitham Road Sheffield United Kingdom S10 2SJ

### Study participating centre Northampton General Hospital

Cliftonville Northampton United Kingdom NN1 5BD

### Study participating centre

### Norfolk & Norwich University Hospital

Colney Lane Norwich United Kingdom NR4 7UY

# Sponsor information

### Organisation

University of Warwick (UK)

### Sponsor details

Warwick Medical School Medical School Building Coventry England United Kingdom CV4 7AL

### Sponsor type

University/education

#### **ROR**

https://ror.org/01a77tt86

# Funder(s)

### Funder type

Charity

### **Funder Name**

Cancer Research UK (CRUK) (UK)

### Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

### **Funding Body Type**

Private sector organisation

### **Funding Body Subtype**

Other non-profit organizations

#### Location

United Kingdom

### **Results and Publications**

### Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal.

### Intention to publish date

31/12/2019

### Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### **Study outputs**

Output type	<b>Details</b> results	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		05/01/2019		Yes	No
Plain English results		06/02/2019	29/10/2021	No	Yes
HRA research summary			28/06/2023	No	No